摘要
本文从三个方面，在回顾和综述了常见胃肠肿瘤(胃癌、结直肠癌)诊治现状和新进展的基础上初步总结了刘沈林教授诊治胃肠肿瘤的中西医结合学术思想与临床实践。
第一部分概述了现代医学对常见胃肠肿瘤的诊疗现状及最新动态，总结了中医药及中西医结合防治胃肠肿瘤的进展，并分别指出其各自特点和存在问题。根据研究现状，强调了中西医结合模式和中医药辨证论治在胃肠肿瘤诊治中的优势和特点，指出在学术指导思想及方法上应扬长避短、优化组合，开展深入的研究和实践总结。
第二部分学习和探讨刘沈林教授诊治胃肠肿瘤的中医临床经验和其主要学术思想。根据三年跟师临床学习体会，从中西医结合是治疗胃肠肿瘤的重要途径、个体化治疗原则是临证的必由之路、带瘤生存是晚期胃肠肿瘤姑息治疗的可行途径、心理调护是提高患者生存质量的重要环节、中西医综合治疗是胃肠肿瘤诊疗的方向等五个方面阐述了导师的中西医结合学术思想。
第三部分从导师辨证结合辨病治疗胃肠肿瘤用药经验、典型病案、经验选萃等角度总结刘沈林教授的临床实践，体现了导师中西医结合治疗胃肠肿瘤方面的学术思想。
On the basis of looking back and summing up the present situation and new progress onthe diagnosis and treatment of common gastrointestinal tumors(gastric cancer andcolorectal cancer), this paper, from three aspects, preliminarily summarizes professorShenlin Liu's academic ideology and clinical practice on combining traditional Chinesemedicine(TCM) and Western medicine for common gastrointestinal tumors.
The first aspect minutes and states generally a novel development and the presentsituation of diagnosis and treatment in modern medical science for common gastrointestinaltumors. It summarizes the progress on prevention and cure of common gastric intestinaltumors by TCM or combining traditional Chinese and Western medicine and points out itscharacteristic and existent problems respectively. According to present situation, paperemphasized the characteristics and the advantages by combining TCM and Westernmedicine's pattern and treatment based on syndrome differentiation of TCM in diagnosisand treatment of gastrointestinal tumors and points out that the academic guiding ideologyand methods for gastrointestinal cancer should foster their each strengths and circumventtheir each weaknesses, and ,with optimal combination, conduct thorough research andclinical practice.
Second part studies and probes into professor shenlin liu's academic thoughts andclinical experiences of TCM. According to following my advisor to study cognition forthree years, this paper, from five aspects ,①Combining TCM and Western medicine is animportant method of Treating gastrointestinal tumors,②The treatment principle ofindividualization is the sole way of clinical practice,③Survival with tumor' is the feasibletactics in management of cancer patients with the advanced condition,④Psychologicalregulation and care is the significant link that raise patient's quality of life(QOL),⑤Combining TCM and Western medicine is the future direction of diagnosing and treatinggastrointestinal tumors, elaborated his academic thoughts on combining TCM and Westernmedicine.
Third part summarizes professor shenlin liu's clinical experiences of integratingsyndrome-differentiation with disease-differentiation, from drug usages, introduction oftypical cases and selection of clinical experience etc, which embody his academic thoughtson combining TCM and Western medicine for treating gastrointestinal tumors.
Finally, the paper puts forward my own directions in research and clinical practice of oncology by means of combining TCM and Western medicine.
引文
[1]．谭诗云，沈克祥，沈磊，等．胃癌术前超声内镜检查与肿瘤血管内皮生长因子表达的检测分析．中华普通外科杂志，2005，20：713-715．
[2]. Tseng LI, Mo LA, Tio TL, et al. Video-endoscopic ultrasonography in staging gastric carcinoma. Hepatogastroenterology, 2004, 47:987-900
[3]. Bhunchet E, Hatakawa H, Sakai Y, et al. Fluoresce in electronic endoscopy: a novel method for detection of early stage gastric cancer not evidence to routine endoscopy. Gastrointest Endosc, 2002, 55:562-571
[4]. Mataki N, Nagao S, Kawagughi A. Clinical usefulness of a new infra red videoendoscope system for diagnosis of early stage gastric cancer. Gastrointest Endosc, 2003, 57:336-342
[5]. Dux M, Richter GM, Hansmann I, et al. Helical hydro-CT for diagnosis and staging of gastric carcinoma. J Comput Assist Tomogr, 1999, 23:913-922
[6]．李引，黄奕华，黄美近．超声内镜与CT对胰腺及壶腹部周围肿瘤的术前诊断价值．中华普通外科杂志，2005，20：757-759
[7]．张谢夫，吕建峰．胃癌术前螺旋CT分期的临床意义．中华普通外科杂志，2003，18：503-504
[8]．郝希山主编．肿瘤学新进展，2005，4-5
[9]. Minami T, Nishimura S, Asagoe K. Primary gastric plasm acytoma at a early stage unremarkable effect of eradication of helicon-bacter pylori. Int Med, 2003, 42:370-372
[10]．吴景良，韩喜春，刘俊，等．幽门螺旋杆菌的毒素相关蛋白基因与胃癌的相关性的研究．中华普通外科杂志，2002，17：463-464．
[11]. Genta RM. The gastritis connection: prevent and early detection of gastric neoplasms. J Clin Gastroenterol, 2003, 36:44-49
[12]. Skopelitou AS, Mitselou A, Katsanos KH. Immunohistochemical expresion of Fhit protien in Helicobacter pylori related chronic gastritis, gastric precancerous lesions and gastric carcinoma: correlation with inventional clinicopathologic parameters. Eur J Gastroenterol hepatol, 2003, 15:515-523
[13]．任本，朱晓玉，徐令鸽，等．胃癌及癌前病变DNA含量及细胞增殖活性检测的 临床意义．中国肿瘤临床，2003，30：17-19
[14]．邵春奎，朱正纲，苏组兰，等．胃癌组织中P53、c-erb-2、EGFR、nm23、E-cadberin基因表达及预后价值．癌症，2000，19：666-670
[15]．张亮，王维娜．胃癌MSI、hMLM1基因甲基化及其蛋白表达研究．中国肿瘤临床，2003，30：325-327
[16]. Kobayashi K, Okamoto T, Takayama S, et al. Genetic instability in intestinal metaplasia is a frequent event leading to differentiated early adnocarcinoma of the stomach. Eur J Cancer, 2000, 36:1113-1119
[17]. Huang TJ, Wang JY, Lin SR, Lian ST, Hsieh iS. Overexpression of the c-met protooncogene in human gastric carcinoma--correlation to clinical features. Acta Oncol. 2001, 40:638-43.
[18]. Kozma L, Kiss I, Hajdu J, Szentkereszty Z, Szakall S, Ember I. C-myc amplification and cluster analysis in human gastric carcinoma. Anticancer Res. 2001, 21:707-10.
[19]．韩诤波，李凡，杨雪飞，等．胃癌线粒体DNA拷贝量降低：一种新的肿瘤标志物．中国肿瘤临床，2004，31：244-247
[20]. Hiyama E, Yokoyama T, Tatsumoto N, et al. Telomerase activity in gastric cancer. Cancer Res, 1995, 55:3258-3262
[21]. DenhardtDT, Giachelli CM, Rittling SR. Role of osteopontin in cellular signalling and toxicant injury. Ann Rev Pharmacol Toxicol, 2001, 41:723-749
[22]．孙砚军，姜希宏，王永胜，等．骨桥蛋白mRNA在胃癌中的表达及临床意义．中华肿瘤杂志，2005，27：292-294
[23]．符学松，白文元，姚希贤，德等．胃癌患者假尿嘧啶核苷测定的临床意义．中国肿瘤临床，2002，29：706-708
[24]．[28] 邢军，徐矗，刘文天，等．胃癌相关基因gel的克隆及其功能预测．中国肿瘤临床，2005，32：1148-1151
[25]. Rosenberg R, Hoos A, Mueller I, et al. Impact of cytokeratin-20 and carcinoembryonic antigen mRNA detection by RT-PCR in regional lymph nodes of patients with colorectal cancer. Br J Cancer, 2000, 83:1323-1329
[26]．王贵英，李勇，王士杰，等．胃癌患者外周血及骨髓微转移检测的临床意义．中国肿瘤临床，2004，31：4052407．
[27]．罗晓勇，薛兆石，王平，等．胃癌患者外周血癌胚抗原CEAmRNA表达的意义．中华普通外科杂志，2004，19：255-257
[28]．工藤进英，大肠内视镜插入法．东京：医学书院，1997．9
[29]．郑之田．胃肠病学．北京：人民出版社，1986．55
[30]. Cascinu S, Staccioli MP, Gas parina G, et al. Expression of vascular endothelial growth factor can predict event free survival in stage Ⅱ colon cancer. Clin Cancer Res, 2000, 6(7):2803
[31]. Akbulut H, Altuntas F, Akbulut KG, et al. Prognostic role of serum vascular endothelial growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine, 2002, 20:184-190
[32]. Werther K, Christensen IJ, Brunner N, et al. Soluble vascular endothelial growth factor levels in patients with primary colorectal carcinoma: The Danish RANX05 Colorecyal Cancer Study Group. Eur J Surg Oncol, 2001, 26:675-663
[33]. Wheelock MJ, Johnson KR. Cadherins as modulators of cellular phenotype. Cell Dev Biol, 2003, 19:207-235
[34]. Bondi J, Bukholm G. An increase in the number of adhesion proteins with altered expression is associated with an increased risk of cancer death for colon carcinoma patients. Int J Colorecal Dis, 2006, 21(3):231-237
[35]. Takeacki K, Yamaguchi A, Urano T, et al. Expression of CD44 variant exon 8-10 in colorectal cancer and its relationship to metastasis. Jpn J Cancer Res, 1995, 86(3):292-297
[36]. Zmazeki E, Koyama S, Maruyama T, et al. Expression of epidermal growth factor receptor and CD44 splicing varaiants sharing exon 6 and 9 on gastric and esophageal carcinomas: a two-colorflow-cytometric analysis. Gastroenterology, 1996,110(2):362-369
[37]. Bendardaf R, Elzagheid A. E-cadherin, CD44s and CD44v6 correlate with tumor differentiation in colorectal cancer. Oncol Rep, 2005,13(5):831-835
[38]．尹浩然，朱正纲，林言箴．进展期胃癌外科综合治疗的方法与步骤．外科理论与实践，2000，5(3)：134-135．
[39]．朱正纲，严超，陈克敏，等．内镜超声检查与多层螺旋对胃癌术前分期的对比研究．中华胃肠外科杂志，2002，5：99-103．
[40]．尹浩然，陈军，朱正纲．远端胃癌根治术(2)的手术方法及要点．中国现代手术学杂志，2002，6(2)：101-104．
[41]. Fujimoto S, Takahashi M, Muton T, et al. Successful in tape ritoneal hyperthemic chemoperfusion for the prevention of the prevention postoperative peritoneal recurrence in patients with advanced gastric cancer. Cancer,1999,85:529-534
[42]. Yonemura Y, Kinoshita K, Fujimura T, et al. Correlation of the histological effects and survival after neoadjuvant chemotherapy on gastric cancer patients. Hepatogastroenterology, 1996, 43:1260-1272 [43]. 陈龙邦, 刘福坤. 循证肿瘤治疗学. 郑州大学出版社, 2004:253-258
[44]. Macdonald JS, Smalley Sr, Benedetti J, et al. Chemotherapy after surgery compared with surgery alone for adnocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001,345:725-730
[45]. MoiseyenkoVM, Ajani JA, Tjulandin SA, et al. Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and fluorouracil (F) to CF in patients(pts) with metastatic gastric adnocarcinoma (MGC). J Clin Onc, Proc Am Soc Clin Oncol, 2005, 23:abstract 4002
[46]. Al-Batran S, Hartmann J, Probst S, et al. A randomized phase III trial in patients with advanced adnocarcinoma of the stomach receiving first-line chemotherapy with fluorouracil leucovorin and oxaliplatin (FLO) versus fluorouracil leucovorin and cisplatin (FLP). J Clin One, Proc Am Soc Clin Oncol,2006, 24: abstract 4016
[47]. Peeters M, Van Laethem JL, Baert F, et al. Phase II study of irinotecan+ 5FU/FA for patients with previously treated advanced gastric cancer. J Clin Onc, Proc Am Soc Clin Oncol, 2004, 22:abstract 4076
[48]. Jin ML, Shen L, Hu B, et al. Capecitabine (X) combined with cisplatin(P) as 1~(st)-line chemotherapy in Chinese patients (pts) with advanced gastric cancer (AGC). J Clin One, Proc Am Soc Clin Oncol, 2004, 22:abstract 4047
[49]. Veronese ML, Dwyer PJ. Monoclonal antibodies in the treatment of colorectal cancer. Eur J Cancer, 2004,40:1292-1301
[50]. Shah MA, Ramanathan Rk, Ilson D, et al. Final results of a multicenter phase II study irinotecan(CPT), cisplatin (CIS), and Bevacizumab (BEV) in patients with metastasticgastric or gastroesophgeal(GEJ) adnocarcinoma. Proc Am Soc Clin Oncol, 2006, 24:abstract 4020
[51].Kahl BS. Update :gastric MALT lymphoma.Curr Opin Oncol, 2003,15 :347-352
[52]. Monig SP, Baldus SE, Hennecken JK, et al. Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology, 2001, 39:597-602
[53]．郑树．我国结直肠癌研究现状．实用肿瘤杂志，1996，24(11)：99．
[54]．郝希山主编．肿瘤学新进展，2005，86-90
[55]. Arkenau H, Schmoll H, Kubich=ka S, et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastastic colorecyal cancer (MCRC): Results of the safty and efficacy analysis. Proc Am Soc Clin Oncol, 2005, abstract 3507
[56]. Popa EC, Lou W, Hochster H, et al. A phase Ⅱ study of ORZEL (UFT+LV) in elderly (=75 years old) patients with colorectal cancer results of ECOG 1299. Proc Am Soc Clin Oncol, 2005, abstract 3608
[57]. Rougier P, Raoul JL, Laethem V, et al. Cetuximab+FOLFIRI as-first line treatment for metastastic colorectal CA. J Clin Oncol, 2004, 22:3513-3517
[58]. Susman E. Rash correlates with tumor response after Cetuximab. Lancet Oncol, 2004, 5:647-649
[59]. Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF; a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys, 2004, 58:984-990
[60]. Vanhoefer U, Tewes M, Rojo E, et al. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol, 2004, 22;175-184
[61]．凌扬．易瑞沙(IRESSA)单药治疗化疗失败的非小细胞肺癌的临床评价．海南医学，2006，17(12)：7-8
[62]. Daneshmand M, Parolin DA, Hirte HW, et al. A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastastic colorectal cancer patients. Clin Cancer Res, 2003, 9:2457-2464
[63]. Fisher GA, Kou T, Cho CD, et al. A Phase Ⅱ study of gefitinib in combination with FOLFOX-4 (IFOX) in patiets with metastastic colorectal cancer. J Clin Oncol, 2004, 22;3514-3519
[64]. Townsley C, Major P, Siu LL, et al. Phase Ⅱ study of OSI-774 in patients with metastastic colorectal cancer. Gastrointest World Symn, 2004 abstract 222
[65].Giatonio BJ, Catalano PJ, Meropol NJ, et al. High-dose bevacizumab improves survival when combined with FOLFOX-4 in previously treated advanced colorectal cancer. Results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol, 2005, 3;2-9
[66]. Hochester HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin/fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastastic colorectal cancer(mCRC): Final analysis of the TREE-Sduty. J Clin Oncol, 2006, abstract 3510
[67].Posey J, Yang B, et al. Aphase I trial of an anti-KDR (VEGFR) chimeric antibody in patients with liver metastases in colorectal cancer(CRC). Proc Am Soc Clin Oncol, 2002, 21: 63-69
[68]. Rao S, Cunningham D, Gramont A, et al. Phase III double-blind placebo-controlled study of famesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Oncol, 2004,22:3950-3957
[69]. King J, Zhao J, Clingan P, et al. Randomized double blind placebo control study of adjvant treatment with the metalloprotienase inhibitor mamastat in patients with inoperable colorectal hepatic metastases significant survival advantage in patients with inmusloskeletal side-effects. Anticancer Res, 2003,23:639-645
[70].Blanke CD, Benson AB, et al. . A Phase II trial of celecoxib irinotecan, 5-fluorouracil and leucovorin in patients with unresectable or metastatic colorectal cancer. Proc Am Soc Clin Oncol, 2002, 21: 505-511
[71]. Lin E, Ayers GD, Crane C, et al. Celecoxib, a selective cyclooxyenase-2 (COX-2) inhibitor ameliorated capecitabine (X) hand & foot syndrome (HFS) & enhanced survival in metastatic colorectal cancer. J Clin Oncol,2004,22:3584-3589
[1]．胡丕丽，黄火文，张蓓．活血化瘀汤对鼻咽癌放射治疗患者舌象及血液流变性的影响．中医杂志，1996，37(2)：104～106
[2]．韦金育．原发性肝癌舌象的临床观察及其与微量元素关系的研究．浙江中医杂志，1988，23(11)：518～520
[3]．陶晓辰．原发性肝癌患者的脉、舌象与生化免疫关系的探讨．中国中西医结合杂志，1988，8(7)：405～406
[4]．许文林，敖忠芳，陈宝安．汉防己甲素逆转血液系统肿瘤细胞多药耐药的临床研究．中华内科杂志，2001，40(9)：633
[5]．蔡宇，蔡天革，唐凤德等．补骨脂素逆转K562／ADM多药耐药系耐药性的研究．中国肿瘤临床，2004，15(3)：156
[6]．张育，顾健，孙振华等．当归药物血清逆转K562／A02细胞对阿霉素耐药性的初步观察．中药药理与临床，2005，21：43-44
[7]．陈小红，高瑞兰，牛泱平等．人参皂甙对白血病耐药细胞化疗药物敏感性的研究．浙江中西医结合杂志，2002，12：206-208
[8]．王欣，麻柔．人参单药及其组分对造血影响的基础研究与临床应用．中国中西医结合杂志，2006，12：1139-1141
[9]．王济，顾立刚，王庆国等．肝郁脾虚因素对S180荷瘤小鼠肿瘤生长和T细胞免疫功能的影响．北京中医药大学学报，2003，26(5)：45-48
[10]．高铭鑫，隋自洁，杨洪群，等．人参根总皂苷的抗DNA损伤与抗突变效应．中国药理学与毒理学杂志，1997，11(2)：113
[11]．赵凤鸣，王明艳，吴丽丽，等．四君子汤六味地黄汤抗突变作用机理的实验研究．中医药学刊，2003，21(2)：231-235
[12]．刘铭球，吴天鹏，朴炳奎，等．黄芪注射液及扶正流浸膏对大鼠诱发性肺癌抑制作用的实验研究．中国中西医结合外科杂志，1996；2(4)：265
[13]．冯利，林洪生．榄香烯对Lewis肺癌小鼠基底膜及细胞外间质影响的实验研究．中国肿瘤临床，2005，15：891—894
[14]．陈小红，高瑞兰，钱煦岱等．人参皂苷诱导人T淋巴细胞白血病细胞株凋亡的研究．白血病·淋巴瘤，2005，14(4)：217-219
[15]．杨勇，杨宏新，闫晓红．羧甲基茯苓多糖抗小鼠白血病凋亡药理学研究．肿瘤研究与临床，2005，17(2)：83-85
[16]．任德莲，钟德生，徐晓玉等。黄芪和地黄对食管癌TIL增殖及体外抗肿瘤作用的研究．华西药学杂志，2000，15(3)：161-163
[17]．吕苏成，曹玛莉，曹巧莉．茯苓多糖对肺癌患者细胞免疫功能及临床疗效的观察．上海免疫学杂志，1994，21(2)：109
[18]．方美云，王忠裕，王一．细胞因子联合人参皂甙及三氧化二砷诱导HL-60细胞向树突状细胞分化的实验研究．实用癌症杂志，2005，20(1)：15-19
[19]．黄光琦，袁淑兰，周宏远，等．丹参酮诱导人宫颈癌ME180细胞的分化．中国药理学与毒理学杂志，1996，10(4)：285
[20]．钱军，秦叔逵．抗癌新药-榄香烯的药理与临床．中国肿瘤临床，1996，23(6)：453
[21]. Chou W C, Dang C V. Acute promyelocytic leukemia:recent advances in therapy and molecular basis of response to arsenic therapies. Curr Opin Hematol, 2005, 12(1): 1-6
[22]．梁蓉，杨平地，陈协群．川芎嗪和(或)环孢素A对HL60／HT细胞耐药的逆转．中华内科杂志，1999，38(4)：260
[23]．黎丹戎，张玮，唐东平等．黄芩素对卵巢癌耐药细胞株A2780／ADM逆转作用实验研究。肿瘤，2004，2：111-113
[24]．张育，顾健，孙振华等．当归药物血清逆转K562／A02细胞对阿霉素耐药性的初步观察．中药药理与临床，2005，4：43-44
[25]．徐庆乐，杨锋．香菇多糖、银耳多糖对荷瘤小鼠的免疫调节作用．浙江临床医学。2002，10：730-731
[26]．孙继萍，肖伟．黄芪对人肺癌细胞株Th2型细胞因子的逆转作用．山东医药。2005，4：36-37
[27]．徐立生，曲长芝，马志铨等．抗癌药物巴豆生物碱、顺铂对红细胞膜的作用．中华肿瘤杂志，1995，17(2)：115～117
[28]．余上才，章育正．牛膝多糖抗肿瘤作用及免疫机制实验研究．中华肿瘤杂志，1995，17(4)：275
[29]．黄光琦，袁淑兰，周宏远，等．丹参酮诱导人宫颈癌ME180细胞的分化．中国药理学与毒理学杂志，1996，10(4)：285
[30]．张娜，蒋勇军，邹建卫，等．CDK4与靛玉红及其衍生物复合物结构的模建．化学学报，205，9：809-813
[31]．楼芳，秦叔逵，陈惠英．三氧化二砷对人类肝癌细胞株端粒酶活性的影响．临床肿瘤学杂志，2006，4：250-253
[32]．唐武兵，倪宏，曾文铤，等．槲皮素对热休克诱导人肝癌HepG2细胞HSP70和P-gp表达的影响．广州医学院学报，2002，3：1-5
[33] 王冠庭．脾胃学说与胃癌关系的研究．中国中西医结合脾胃杂志，1997，(1)：3
[34] 王佑民．小剂量穴位注射配合中草药治疗恶性肿瘤．医学情况交流，1974，(9)：37
[35] 周阿高，顾伟威，洪声．254例胃恶性肿瘤患者正虚血瘀病机的研究．中国肿瘤，2002，11(6)：333
[36] 张锡君．胃癌的中医药临床研究进展．中医杂志，1987，28(9)：10
[37] 刘学纹．幽门螺杆菌与胃癌．中华消化杂志，1993，13(2)：100
[38] 张锦增．人胃癌发生的分子生物学研究．中华消化杂志，1993，13(4)：187
[39] 李晓斌，夏天，张仲海，等．中药消萎灵对大鼠慢性萎缩性胃炎胃粘膜血流量和血浆胃动素的影响．第四军医大学学报，2002，23(9)：277
[40] 胡鸿毅，郑红斌，陆雄，等．胃祺饮阻断胃癌前病变组织增殖作用的实验研究．中国中西医结合消化杂志，2000，9(1)：32
[41] 唐纯志，劳绍贤，胡玲，等．胃炎消治疗胃癌前病变对细胞凋亡及相关基因表达的影响．中国中西医结合脾胃杂志，2000，8(5)：25
[42] 宋家驹．健脾中药抗胃癌术后转移的研究．现代中西医结合杂志，2004，13(22)：2956
[43] 于庆生，陈子义，唐雄荣．芪黄煎剂对胃癌切除后早期淋巴细胞免疫功能的影响．中国实验方剂学杂志，1996，2(2)：13
[44] 王守章，高加亮，等．中药防治胃癌术后化疗毒副反应267例．国医论坛，1996，11(4)：24
[45] 胡萍萍，尤志伟．中西医结合治疗期胃癌术后45例．南京中医药大学学报，1996，12(4)：42
[46] 许殿元．中药癌康复加化疗治疗进展期胃癌术后的临床观察．山西中医，1993，9(4)：14
[47] 刘宇，伍晋森．抗癥号结合化疗治疗晚期胃癌临床观察．山东中医药大学学报，2002，26(6)：444～445
[48] 凌扬．中西医结合治疗奥沙利铂所致感觉神经障碍的临床观察 内蒙古中医药杂志，2007，(4)
[49] 张新．孙桂芝治疗大肠癌经验．山东中医杂志，1998，17(4)：173．
[50] 陈乃杰．中医辨证配合方案治疗晚期大肠癌26例临床观察．福建医药杂志，1998，20(6)：66．
[51] 邵梦扬．直肠癌中医治疗经验谈．河南中医，1998，18(5)：268．
[52] 张福忠，于庆生．中西医结合治疗结肠癌106例．中国中西医结合外科杂志，1997，3(4)：253．
[53] 潘明继．中西医结合治疗260例中晚期大肠癌的疗效观察．中医杂志，1996，37(4)：218．
[54] 王文海．肠益煎治疗大肠癌术后50例临床观察．浙江中西医结合杂志，2000，10(6)：325．
[55] 许环应．大肠癌术后加用扶正解毒中药的疗效观察．上海中医药杂志，1996，(2)：12．
[56] 刘静安，张悦红．中西医结合治疗大肠癌术后154例临床观察．中草药，2000，31(5)：367．
[57] 郭志雄．扶正抑癌汤在大肠癌术后治疗中的作用观察．中国中西医结合外科杂志，1999，5(1)：10．
[58] 文小平．平消胶囊联合介入化疗及肝体外照射治疗结直肠癌术后肝转移的比较研究．肿瘤防治研究，1998，25(3)：4．
[59] 张明智．华蟾素治疗中晚期恶性肿瘤疗效观察．中国中西医结合杂志，1994，14(7)，438．
[60] 上海第二医科大学附属瑞金医院中医科．康赛迪胶囊治疗30例大肠癌患者临床观察．中国临床，1998，9：32．
[61] 金洪传．康莱特注射液对人大肠癌细胞的生物治疗增敏作用研究．实用肿瘤杂志，1999，14(5)：308．
[62] 尤建良．赵氏微调平衡法治疗四期胃癌176例临床研究．吉林中医药，2000，20(5)：10．
[1] 姜春华．在中西医结台中对辨证论治的几点看法．新医药学杂志．1977(9)：5
[2] 邓铁涛．辩证论治是中医学之精髓．中医药通报 2005(1)：2～3
[3] 李德华．中西医结合抗癌作用的优势互补．中国中西医结合外科杂志，2006，12(4)：319-320
[4] 李岩．肿瘤临证备要[M]．第3版．北京：人民卫生出版社，1998
[5] 周岱翰主编．临床中医肿瘤学[M]．北京：人民卫生出版社，2003
[6] 朱文锋主编．中医诊断学[M]．北京：中国中医药出版社，2002
[7] 丰哲，黄有荣，王银山．中西医结合临床思路浅谈——论辨证与辨病的关系．医学与哲学，2006，27(2)：77-78
[8] 孙丰雷，高华．中医实践的个体化特征与中医学术的整体论思想．中国处方 药，2004，8：60-61
[9] 舒鹏．刘沈林教授治疗慢性泄泻经验介绍．四川中医，2004，22(7)：9-10
[10] 刘艺．刘沈林教授治疗脾胃病常用药对集锦．江苏中医药，2005，26(9)：34-35
[11] 刘沈林．徐景蘩教授论脾阴虚和胃阴虚的辩治特点．南京中医学院学报，1995，11(1)16-17
[12] 刘沈林．徐景蘩教授久泻证治琐谈．实用中医杂志，1995，9(2)：4-6
[13] 骆天炯．刘沈林治疗肠易激综合征的辨证思路．湖北中医杂志，2002，24(3)：15-16
[14] 陈玉超，舒鹏．刘沈林教授运用寒温并用法调治消化道肿瘤经验．吉林中医药，2004，25(1)：11-12
[15] 陈泽霖主编．舌诊研究[M]．上海：上海科技出版社，1982
[16] 凌扬．浅论“通法”在消化道肿瘤姑息治疗中的应用．中医药导报，2006，12(11)：11